Share Name Share Symbol Market Type Share ISIN Share Description
Venture Life Group Plc LSE:VLG London Ordinary Share GB00BFPM8908 ORD 0.3P
  Price Change % Change Share Price Shares Traded Last Trade
  0.50 1.39% 36.50 188,344 14:38:09
Bid Price Offer Price High Price Low Price Open Price
35.00 38.00 37.50 36.00 36.00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Health Care Equipment & Services 18.77 0.71 0.42 86.9 31
Last Trade Time Trade Type Trade Size Trade Price Currency
15:16:11 O 50,000 36.00 GBX

Venture Life (VLG) Latest News

More Venture Life News
Venture Life Takeover Rumours

Venture Life (VLG) Discussions and Chat

Venture Life Forums and Chat

Date Time Title Posts
29/1/202016:22ValueGrowth Investing30,913
10/1/202010:09Venture Life Group plc202
02/4/201509:58Venture Life Group - Intro video-

Add a New Thread

Venture Life (VLG) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
17:16:1136.0050,00018,000.00O
17:16:0236.0050,00018,000.00O
15:37:2836.9520,0007,390.00O
14:27:0037.0057,28721,196.19O
09:35:2836.8010,0003,680.00O
View all Venture Life trades in real-time

Venture Life (VLG) Top Chat Posts

DateSubject
29/1/2020
08:20
Venture Life Daily Update: Venture Life Group Plc is listed in the Health Care Equipment & Services sector of the London Stock Exchange with ticker VLG. The last closing price for Venture Life was 36p.
Venture Life Group Plc has a 4 week average price of 31.50p and a 12 week average price of 28.50p.
The 1 year high share price is 54p while the 1 year low share price is currently 28.50p.
There are currently 83,712,106 shares in issue and the average daily traded volume is 68,818 shares. The market capitalisation of Venture Life Group Plc is £30,554,918.69.
28/1/2020
21:01
apad: Roger Lawson on HLMA " This morning (25/10/2019) I attended a presentation by Halma Plc (HLMA) in the Investec offices. It was given by Charles King, Head of Investor Relations and it was a very professional presentation unlike many we see. I have held shares in the company for four years and it confirmed that my choice of it as an investment was sound. But I did learn a bit more. I’ll cover some of the key points that were made. This company has strong fundamental growth drivers. It has grown both organically and by acquisition over 45 years and now has 45 companies in the portfolio which primarily operate independently. One might call it a conglomerate. It focuses on life saving technology businesses – in essence “safer, cleaner, healthier”, in global niche markets. These are often regulated markets which helps on defensibility and growth. Demographic trends help as more people who are older and fatter promote growth and higher regulatory standards also move in. There is a lot of diversity in the products. They aim for 15% growth per annum and have 6,000 staff in total. They bet strongly on “talent” to run the businesses. In essence there are many little companies all run by entrepreneurs who are left to operate as they wish. These people are paid on the basis of profit achieved in excess of the cost of capital but one requirement they look at when recruiting is that they must have “low egos”. There is only a small group of central staff handling some corporate functions. Their focus is on acquiring companies with low capital intensity and ROTIC of greater than 16% when their cost of capital is about 8%. They are very diversified internationally but see opportunities to grow more in Asia/Pacific and other developing markets. The high share price was questioned (or as one person put it: “it’s in nose bleed territory”). It’s currently on a forecast p/e of 32 according to Stockopedia which is higher than when I purchased shares in 2015 but the share price has more than doubled in that period. This company is like many high revenue/profit growth companies – they never look cheap but simply grow into their share price. However the share price has fallen back of late like a lot of highly valued technology stocks that I hold. The speaker attributed this to market trends, not management share selling. Growth companies tend to go out of fashion as economic headwinds appear. But if they stick to the business model, with the high return on capital and sensible acquisitions, I doubt they can go far wrong. In summary a useful and enlightening meeting for a company that until recently kept a low profile. But it is now in the FTSE-100 (market cap £7 billion)."
23/1/2020
13:31
apad: "Elsewhere in sellside, Morgan Stanley likes Renishaw. A “near-term inflection in Asia machine tool growth” means Renishaw “can deliver a stronger than consensus earnings print and drive valuation below long-term average levels by CY21,” it says. Renishaw’s shares have decoupled from global automation peers: The shares decoupled from global automation & UK Engineering peers on 3 profit warnings in 2019, driven by slowing machine tool activity in Asia. The shares have undershot both groups by ~40% over the last 18 months. It’s one of only 2 UK Engineers (along with Vesuvius) that have seen a share price decline over the last 12M (-11% vs SXNP +28%) and is the most consensual sell in the sector. There is a strong relationship between Asian machine tool growth and Renishaw’s growth, multiple and share price. Our MS Quant team ... predicts a strong inflection in the machine tool series by mid-year. Mapping prior downcycles in Asian machine tools & for Renishaw suggests it can deliver a stronger growth inflection than current consensus assumes. Our EPS estimates sit well above consensus (FY20/21/22 +7%/+42%/+23%). Headline valuation extreme, but superior growth profile suggests it’s a good entry point: Renishaw trades on consensus CY20 P/E of 35.0x & EV/EBIT of 28.8.x vs LTA of ~19x / ~17x, respectively. However, our stronger than consensus growth inflection pushes our implied valuation by CY21 to 19.4x P/E & 16.6x EV/EBIT, i.e., in-line with LTA, and our fair multiple analysis suggests a 4,500p PT is reasonable."
23/1/2020
08:53
redartbmud: tlatsatt Good post, explaining your thoughts and strategy behind your SOS investment. I had been musing on the broader topic myself this morning. I have come to the realisation that small cap growth companies require an additional level of micro-management compared to their larger peers: 1. They are more vunerable because of size. 2. The share price is more volatile, and often overreacts to statements, updates etc. 3. The shareholder base has a different set of expectations, and is in many respects a different set of investing individuals. That also applies, to some extent, to the institotional investment teams. It means that we have to be faster moving and more decisive, when it comes to those holdings. If I buy a big cap I can reasonably expect it to perform in a certain way, as long as management don't screw things up. Over the longer term, I can expect a reasonable return, in relation to the general market, both in dividends and capital appreciation. With a small cap that just isn't the case: Results significantly better than forecast, off into the stratosphere. Results significantly worse than forecast, off into the depths. Forward statements give the same effect. It is far more important to understand the fundamentals of the small cap. In recent times Equals, Xpd, Ztf and Vanl have all hit problems. Once they were identified, the share price immediately bombed, and has not recovered. The sensible answer was to sell at the opening bell and take the hit. They are all thrashing around, trying to address their issues, and after months we have not seen any visible improvement in trading. The share price becomes becalmed, at the bottom, with dividends often cut, but even before that act, those returns were pitiful in relation to the cost of capital. In fact there has often been a second and maybe third leg down in the share price. Rambling from Reading. red
31/12/2019
11:51
apad: Below are the collected comments on peoples 2019 Comparison entries. 2019 Reviews. janeann Key lesson for me from 2019 is how to better determine both when to sell and what are genuine btfd opportunities (and what are not). More patience to see just how far a fall is going is clearly required. And as someone else said never sell GAW. apad Abcam (ABC) This is up 30% YTD, but has been down to zero in April and October. I have lost confidence in the management and have been selling down. It is now my 11th largest holding at 2.4% of Stairway. Fever Tree (FEVR) This is now about flat on the year having been up 45%. I still have confidence and am monitoring US activity as close as I can. It is 20% of Stairway. Boo Hoo (BOO) This is the standout performer, up about 78% on the year. It is the clear leader in 'immersive brands' and has some new brand names from company failures. It will benefit from failures in the High St. so I am riding this bad baby. It is 22% of Stairway. Bioventix (BVXP) This has been up 30% in the year and is now down to breakeven. In my opinion it is the best value on the market and I am buying more at every opportunity. It is PI driven and they are impatient. I believe that the hs-troponin income will increase at a much more rapid rate than the forecasts. Renishaw (RSW) This company is dependent on the global cycle and I knew this but ignored it. It is down about 7% having been down about 20%. It does this when it doesn't deserve it. I intend to top-slice before the next results. Valhamos D4T4 - up 9% having been up 46% at one stage; long term growth story seems to be intact but this is masked in the short term by the increasing switch from upfront licence sales to the SaaS model. Still lowly rated (P/E 14) and will include in next year’s comparison. 7% of portfolio. XPP - will also include again; 37% increase. Recovery from lows at beginning of the year, fears of impact of tariffs and decline in semi conductor industry have eased. Semi-conductor manufacture is building up again with 5G - see recent increases in SWKS and LRCX which I also hold. Largest shareholding at 8% of portfolio. CHH - 94% increase, quietly performs without attracting much interest. The ADVFN board has had 3 posts in last 6 months - my sort of share. GHT - Recovery from last year’s profit warning; today’s news should dispel doubts about current year’s performance; up 69% SDI - up 117%; a good track record up to now of extracting value from acquisitions. Can it last? Will it be another JDG? After a good year I have recently taken out my original stake and will let the rest run. lomax99 BUR - Down c 57% YTD 2019, IMO mis-priced following short attack, looking forward to 2020 US listing. FUTR - A gain of over 200% YTD 2019, expect the ascent to continue. Looking forward to transformation of TI Media pending acquisition. HL. - Up c 6% YTD 2019. Leading D2C platform, long term structural growth story, excellent margins. Active Savings gaining traction. The W effect has been setback. BVXP - Expect troponin to start to gain traction, excellent margins. EYE - Digital promotions, starting to gain traction. Significant market opportunity, not without risk. BUR was painful, FUTR more than compensated for that. Woodford impacted HL. and didn’t particularly help BUR. ACSO and FFX/EQLS were disappointing, sold both, neither holding was significant. Lost money on ACSO, and a reduced profit on EQLS. Should have carried CVSG choice over from the previous year, still hold. attrader XPD - Transport and logistics group acquiring smaller firms in easter Europe. ROI on acquired businesses is around 10% so it might not be a great investment in the long run... It tanked due to missteps and PIs loosing confidence in management. I revisited my thesis and concluded I do not understand the business. Luckily exited the position before disaster struck. GLE - Low cost house builder aiming to double unit production by 2022. It pays decent dividend. Business performance is highly cyclical - needs constant supply of land along with housing demand and availability of mortgages... It is a capital intensive cyclical business. However, ROC is high and chronic shortage of affordable housing in UK will support their profits. Up roughly 20% YTD. IGG - Spread betting business diversifying into SIPP and Index funds. Government is increasing regulation to protect novice punters... Up roughly 15% YTD. I sold out out after final year results. Majority of their spread betting customers loose money. Churn is high. Regulations ever more strict. I am unable to visualise their future prospects so not invested any more. BUR - Litigation finance player investing ever increasing sums of cash for high returns. Low barriers to entry will invite larger players reducing ROI for future investments... It is down 50% YTD after MW highlighted accounting practises and lack of trust in management. I sold out after FY result citing similar issues here. NPSNY (Naspers ADR) - South African tech investor with large stake in Tencent along with other emerging market tech investments. Trading at significant discount to NAV. A crash in tech valuations can dent their performance in coming years... Naspers demerged Prosus & Multichoice. Adjusting for demergers, YTD gain is 0%. I have sold out as expected event has passed. Lauders AMER - Colombian oiler that has taken a share price hit this year but recent news has been excellent and there has been strong director buying. I believe that things will get better in 2019 providing the oil price holds of course. On 15 November 2019 a recommended cash offer for Amerisur Resources plc ("Amerisur") by Geopark Limited ("Geopark") was made at 19.21p. This was a disappointing offer and the 15.88% gain I made on the starting price of 2019 could have been oh so much better! ARS - A junior (puppy) copper play. Again taken a major share price hit recently but if good news comes on drilling, partnering and the Cu price strengthens then the appetite could return quickly. My worst performer of 2019 at a shocking -47.50% due to a poor BOD and the weak Cu price. Things just didn't come together and the share price was very volatile. Didn't pick again but still hold all my shares and would like to top-up but the BOD are not in my good books and hence I have decided against adding any more. If Cu takes-off in 2020 and the BOD finally get their act together things may turnaround significantly for the best. Too much of a gamble for me to keep in the comparison although I hope it all does come good for obvious reasons! HCM - News due before the end of the year so could strengthen significantly if positive. However, it is Chinese and if news is not so good on the trials and alliances it could take a major hit. If Trump continues his Chinese battles then again could be impacted. The 8.17% gain on the start of the year share price could also have been so much better if it were not for the parent company wanting to place a load of shares at quite a discount and for perhaps the anti-China sentiment that gripped the markets after the US levied a whole series of penalties on Chinese companies affecting sentiment in all things Chinese. I am hopeful that 2020 will be a much better year in this respect and HCM will respond accordingly. Hence my retention of it in the comparison for 2020. SIA - One of my dogs! Not a puppy but a badly behaving large one. I think the trainer will have sorted it out by new year and its behaviour will improve. Recent news about its Egyptian acquisition that will hopefully be completed in the first half of 2019 will producing some drilling and get the news flowing again. There may be other M&A activity involving the company in the year. What a dog it remains! Every dog has its day though and 2020 may be it for SIA. I don't want to be disappointed again though so while I still hold in physical shares I will ditch it from the comparison. -24.29 for 2019! 2020 has to be better and it really needs to be in order to re-rate the shares. TXP - Another oiler (oil had better perform well in 2019!) based in Trinidad and Tobago. News due before year end again but some important drilling will be undertaken in 2019 with the potential to significantly change the MKT Cap of the company. Should be exciting! My best performer over the year as the important drilling proved to be a success. More to come on this one I believe and hence I am retaining it among my comparisons for 2020. A gain of 78.40% in 2019 and would hope for at least the same in 2020! Cragside Thanks to all of the contributions during the year which have been interesting, thought provoking, and good to have different points of view. Between Christmas and New Year is a good time for reflection, particularly on what happens to the best laid plans so here goes HUR - Could be a significant year ahead with a lot of action in the North Sea. Fully funded, no debt. Well there was some action and successful hooking up, but the exploratory drilling showed resources not as good expected. Still plenty to go for here though. I was frustrated with the price action not reflecting progress during the year so sold out at 44p in July. Have no regrets yet. SQZ another oiler in the North Sea. No debt, and recent big deal with BP. Difficult to calculate projections but very low PE of 2 approx. Like most oilers, the share price this year is dependent upon the price of oil generally. A year of consolidation for SQZ. Disappointed that a dividend was not started in the year, and beginning to wonder where shareholders fit into things. Sold out in July again at £1.21. Maybe I did not give it a chance. Time will tell. ARE - Fairly recent float in the specialist area of hiring out gear for events particularly large sporting occasions eg Wimbledon, Open golf. Had problems with US tax authorities last year from a company acquired, but a settlement was reached. Expecting a steady if not spectacular performance. What a disaster this was. Management have no idea buying up loss making companies, when they should be concentrating on making a profit on the existing business and growing organically. Maybe a typical over hyped float followed by the inevitable crash. Bailed out on 17/1/19 at 40p. Lost quickly, and badly, but would have been much worse if I had held on. VLE - Must be worth the current share price based on cash alone. Not many new investment as of late, except share buybacks. Management has a good track in turning around companies. Very little went on with this company during the year. 1 sale, no new investments, good special dividend paid out. Steady if unspectacular performer. ARC - Good performer in 2018, and no reason to sell. Small well managed operation with apparently low customer turnover. This is proving to be a well managed outfit in a niche market with growth albeit the share price can be erratic at times. Often mentioned on this board So overall not a good average year for the 5 selected, especially ARE.
29/12/2019
15:39
cragside: Thanks to all of the contributions during the year which have been interesting, thought provoking, and good to have different points of view. Between Christmas and New Year is a good time for reflection, particularly on what happens to the best laid plans so here goes: HUR - Could be a significant year ahead with a lot of action in the North Sea. Fully funded, no debt. Well there was some action and successful hooking up, but the exploratory drilling showed resources not as good expected. Still plenty to go for here though. I was frustrated with the price action not reflecting progress during the year so sold out at 44p in July. Have no regrets yet. SQZ another oiler in the North Sea. No debt, and recent big deal with BP. Difficult to calculate projections but very low PE of 2 approx. Like most oilers, the share price this year is dependent upon the price of oil generally. A year of consolidation for SQZ. Disappointed that a dividend was not started in the year, and beginning to wonder where shareholders fit into things. Sold out in July again at £1.21. Maybe I did not give it a chance. Time will tell. ARE - Fairly recent float in the specialist area of hiring out gear for events particularly large sporting occasions eg Wimbledon, Open golf. Had problems with US tax authorities last year from a company acquired, but a settlement was reached. Expecting a steady if not spectacular performance. What a disaster this was. Management have no idea buying up loss making companies, when they should be concentrating on making a profit on the existing business and growing organically. Maybe a typical over hyped float followed by the inevitable crash. Bailed out on 17/1/19 at 40p. Lost quickly, and badly, but would have been much worse if I had held on. VLE - Must be worth the current share price based on cash alone. Not many new investment as of late, except share buybacks. Management has a good track in turning around companies. Very little went on with this company during the year. 1 sale, no new investments, good special dividend paid out. Steady if unspectacular performer. ARC - Good performer in 2018, and no reason to sell. Small well managed operation with apparently low customer turnover. This is proving to be a well managed outfit in a niche market with growth albeit the share price can be erratic at times. Often mentioned on this board So overall not a good average year for the 5 selected, especially ARE. Will set out the 5 for 2020 in the next couple of days.
29/12/2019
03:56
lauders: Perhaps these five "conviction" picks for 2020 can be added to the comparison out of interest too? Http://www.alignresearch.co.uk/gaming-realms/3248/ As for my performance in the last comparison: AMER - Colombian oiler that has taken a share price hit this year but recent news has been excellent and there has been strong director buying. I believe that things will get better in 2019 providing the oil price holds of course. On 15 November 2019 a recommended cash offer for Amerisur Resources plc ("Amerisur") by Geopark Limited ("Geopark") was made at 19.21p. This was a disappointing offer and the 15.88% gain I made on the starting price of 2019 could have been oh so much better! ARS - A junior (puppy) copper play. Again taken a major share price hit recently but if good news comes on drilling, partnering and the Cu price strengthens then the appetite could return quickly. My worst performer of 2019 at a shocking -47.50% due to a poor BOD and the weak Cu price. Things just didn't come together and the share price was very volatile. Didn't pick again but still hold all my shares and would like to top-up but the BOD are not in my good books and hence I have decided against adding any more. If Cu takes-off in 2020 and the BOD finally get their act together things may turnaround significantly for the best. Too much of a gamble for me to keep in the comparison although I hope it all does come good for obvious reasons! HCM - News due before the end of the year so could strengthen significantly if positive. However, it is Chinese and if news is not so good on the trials and alliances it could take a major hit. If Trump continues his Chinese battles then again could be impacted. The 8.17% gain on the start of the year share price could also have been so much better if it were not for the parent company wanting to place a load of shares at quite a discount and for perhaps the anti-China sentiment that gripped the markets after the US levied a whole series of penalties on Chinese companies affecting sentiment in all things Chinese. I am hopeful that 2020 will be a much better year in this respect and HCM will respond accordingly. Hence my retention of it in the comparison for 2020. SIA - One of my dogs! Not a puppy but a badly behaving large one. I think the trainer will have sorted it out by new year and its behaviour will improve. Recent news about its Egyptian acquisition that will hopefully be completed in the first half of 2019 will producing some drilling and get the news flowing again. There may be other M&A activity involving the company in the year. What a dog it remains! Every dog has its day though and 2020 may be it for SIA. I don't want to be disappointed again though so while I still hold in physical shares I will ditch it from the comparison. -24.29 for 2019! 2020 has to be better and it really needs to be in order to re-rate the shares. TXP - Another oiler (oil had better perform well in 2019!) based in Trinidad and Tobago. News due before year end again but some important drilling will be undertaken in 2019 with the potential to significantly change the MKT Cap of the company. Should be exciting! My best performer over the year as the important drilling proved to be a success. More to come on this one I believe and hence I am retaining it among my comparisons for 2020. A gain of 78.40% in 2019 and would hope for at least the same in 2020!
28/12/2019
13:11
attrader: attrader -> 2020 - CAPRI (CPRI) Capri owns Michael Kors, Versace, Jimmy Choo. These are fast growing brands popular with younger generation especially Asians. Management has been aggressive in expanding the business. Versace & Jimmy Choo's acquisitions were expensive. They opened too many stores along with uncontrolled wholesale growth. Michael Kors bags are now selling in $300 range in some stores due to discounting. This has undermined the exclusivity of brand. Given these issues share price collapsed in 2019. However, management is focussing on correcting their mistakes and growing accessories business under Versace & Jimmy Choo brands. Capri trades for 1x revenue and forward PE of 7x. It should trade a lot higher if management can rebuild trust. - Graftech (EAF) Graftech manufacturers graphite rods for Electrical Arc Furnaces used in steel industry. Needle coke is used as input to produce high quality (UHP) rods. Supply of needle coke comes from refineries and specialist plants. There has not been any new capacity for needle coke in western world for a while. This has resulted in record prices for graphite rods. Graftech owns Seadrift, a needle coke manufacturer, covering 70% of their needle coke needs. This allows them to write long term contracts for a fixed price. Graftech’s contracted revenues for next 5 years covers market cap. Given barriers to entry, low cost operation and high demand for needle, prices for graphite rods are likely to stay high. If it does, Graftech should trade higher than current PE of 5.4x. - Micron (MU) Micron is third largest memory manufacturer after Samsung & SK Hynix. Memory is highly capital intensive business with industry spending $40bn last year alone. This acts as a barrier for any new players to enter the market. In next 10 years, there will considerably higher penetration of electronics in our lives. 5G will require a lot more chips. IOTs are being used to enhance plant operations. Cars will have a lot mot electronics per kg of their body weight. AI & Machine learning needs specialised chips with high memory footprint. Migration to data centres will need more hardware. All of this bodes well for Micron as it is aiming to grow revenue from higher margin systems along with memory chips. Micron trades at trailing PE of 9.8x and will likely be higher in coming years. - Bioventix (BVXP) This antibody test supplier does not need any introduction. Management is hoping for troponin revenue which should support the share price. BVXP trades at PE of 29x. It is not undervalued. However, I don’t have any better ideas. - Cash (£££) Due to lack of ideas, I am nominating cash as a position. I have no idea where market will be in next year but keeping cash as a position to act when there is an opportunity is a nice place to be.
01/12/2019
10:39
redartbmud: Breedon Yes, it has proved to be a massive BFTD. It is a case study in strategy and tactics. The scenario was one where: 1. A major shareholder, closely aligned to another major shareholder had sold the entire stake, without any real explanation for the reasons behind the deal. 2. One of the founders, who had been chairman, has previously sold 50% of a large shareholding, on retirement. 3. There has been an overhang of shares in the market. 4. There are regular large size trades taking place. 6. The PE is relatively modest, but the share price isn't underpinned by by a dividend. I hold a sizeable stake, relative to the size of my portfolio, and the type of share it is. It was quite obvious that the there was a galaring disconnect, in the share price, based on "underlying" fundamentals. The probability of the correction was better than average. The timing of the correction was opaque, given macro market conditions, exacerbated by the two large divestments, although there is an expectation that the recipients of those shares might be expected to hold for the near term. The counter argument being the lack of dividend, hence the need to regularly take capital gains, in lieu of dividends, to create income. Holding a larger number of shares extends the percentage of those non-income generating assets, taking away that opportunity in alternative investments. If the share price recovers quickly then it is a successful trade. If it languishes, in thr depths for months, it is a failure. I am not sure that charting thr share is the answer to a specific set of circumstances. No right answer. red
22/11/2019
08:29
redartbmud: tlatsatt Worth looking at the chart, with the comparison to the FTSE100. Currently the share price has [erformed very well, but historically it has been a train wreck. Maybe better times are on the horizon, at last! From what I have seen of share price movements: the only significant moves have been downwards, on the back of negative news, both or markets and company specific. They have been the subject of very negative press comment. Apart from huge structural business problems, identified by the tintins, the popular press have slaughtered them for their performance, charges, service etc. etc. It is very unusual for the share price volatility to be sufficient to justify a short term trade. Just a few thoughts. red
28/10/2019
19:15
thelongandtheshortandthetall: APAD All is well then 😃 Not sure about SOS for tomorrow. Not sure how many shares were traded today but it made the share price rise 25% and an equal amount of action tomorrow could do the reverse I guess. I hope todays RNS will support the share price till the interims. Not that we can expect too much more info. But they might able to elucidate further on marketing responses up to 27th November. Unless someone or institution is building a position the share price will probably drift for the next few days as the traders move onto pastures new.
Venture Life share price data is direct from the London Stock Exchange
Your Recent History
LSE
VLG
Venture Li..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20200129 19:50:08